We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
NITYR nitisinone 5 mg tablet bottle, Orpharma Pty Ltd, CON-981
Product name
NITYR nitisinone 5 mg tablet bottle
Sponsor name
Orpharma Pty Ltd
Consent start
Consent no.
CON-981
Duration
The consent is effective from the 25 August 2022 until 31 December 2026.
Standard
Subsection 11(5), subsection 8(2) and paragraphs 8(1)(n) and 8(1)(j) of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines (TGO 91)
Non-compliance with standard
The product labels do not include storage conditions in the required format, a machine-readable code in the required format, space for a dispensing label, and do not declare the presence of lactose and sugars.
Conditions imposed
The labels to which this consent applies are those provided with the letter of application and are overstickered with the warning statements “Prescription Only Medicine” and “Keep Out of Reach of Children”, the Australian sponsor’s details and the AUST R numbers as indicated.A ‘Dear Healthcare Professional’ letter as provided to the Therapeutic Goods Administration dated 18 August 2022 must be provided with each of the affected batches. A copy of the Australian approved Product Information document will accompany each ‘Dear Healthcare Professional’ letter.
Import, Supply, &/or Export
Import, supply and export
Therapeutic product type
Prescription medicines